NPCE

NeuroPace, Inc. (NASDAQ:NPCE) is a medical device company founded in 1997 and headquartered in Mountain View, California. The company went public in April 2021 and specializes in developing brain-responsive neuromodulation technology for treating drug-resistant epilepsy. NeuroPace has pioneered the field of closed-loop neurostimulation with its flagship RNS System, which represents the first and only FDA-approved brain-responsive neurostimulation device for epilepsy treatment. The company has evolved from a research-stage organization into a commercial-stage medical device manufacturer, focusing primarily on serving patients with medically refractory focal epilepsy through comprehensive epilepsy centers across the United States.